Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
HCC1806	MK2206	2	72	sigmoid	sigmoid	HCC1806 MK-2206 0 2 72	8	2.831	51.9	0.823	0.0489	320.0	-0.668	0.467	0.981	7.01e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.45e-05	NA
BT-549	Sirolimus	2	72	flat	flat	BT549 rapamycin 0 2 72	8	1.830	Inf	0.569	0.384	0.0	0.569	0.01	0.517	0.113	0.618	Inf	0.642	0.677	0.0	0.642	0.01	0.465	0.153	0.679
BT-549	TGX221	2	72	sigmoid	sigmoid	BT549 TGX-221 0 2 72	8	1.927	17.5	0.772	0.0551	123.0	-1.0	0.562	0.907	0.000795	NA	32.3	0.792	0.949	32.3	3.45e-05	0.58	0.899	0.00102	NA
BT-549	Torin1	2	72	sigmoid	sigmoid	BT549 Torin1 0 2 72	8	1.881	0.0165	0.0298	0.618	0.0147	0.0572	1.03	0.993	4.2e-07	NA	0.0262	0.287	0.52	0.0111	0.306	1.1	0.99	9.68e-07	NA
HCC1806	PI103	2	72	sigmoid	sigmoid	HCC1806 PI-103 0 2 72	8	2.758	Inf	0.898	0.00662	1.71	0.857	1.43	0.781	0.0105	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA
BT-549	Torin2	2	72	sigmoid	sigmoid	BT549 Torin2 0 2 72	8	1.824	0.00997	-0.281	0.767	0.0212	-0.282	0.594	0.975	1.47e-05	NA	0.0177	0.155	0.438	0.00929	0.188	0.734	0.973	2.02e-05	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
Hs 578T	Trametinib	2		sigmoid	sigmoid	Hs578T trametinib 2	8	2.483	0.00633	0.074	0.701	0.00558	0.0362	0.593	0.998	1.32e-08	NA	0.0058	0.214	0.361	0.00257	0.193	0.602	0.998	3.66e-09	NA
BT-549	WYE-125132	2	72	sigmoid	sigmoid	BT549 WYE-132 0 2 72	8	1.780	0.0329	0.0784	0.528	0.0287	0.0811	1.29	0.988	1.59e-06	NA	0.0545	0.333	0.604	0.0236	0.337	1.34	0.986	2.87e-06	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.0	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.0	0.968	0.01	-0.000878	1.0	1.0
BT-549	ZSTK474	2	72	sigmoid	sigmoid	BT549 ZSTK474 0 2 72	8	1.962	0.628	0.144	0.245	0.841	-0.139	0.84	0.995	1.29e-07	NA	0.958	0.334	0.791	0.595	0.163	0.828	0.992	4.28e-07	NA
Hs 578T	Torin1	3		sigmoid	sigmoid	Hs578T Torin1 3	8	2.860	0.0307	0.174	0.514	0.0196	0.176	0.964	0.999	2.01e-09	NA	0.0212	0.218	0.469	0.0119	0.222	1.02	0.998	1.17e-08	NA
Hs 578T	GDC-0980	3		sigmoid	sigmoid	Hs578T apitolisib 3	8	2.831	0.243	0.145	0.315	0.19	0.112	1.02	0.998	4.02e-09	NA	0.179	0.206	0.665	0.114	0.196	1.09	0.999	9.76e-10	NA
HCC38	AS605240	3	72	flat	flat	HCC38 AS-605240 0 3 72	8	1.343	Inf	0.958	-0.0162	0.0	0.958	0.01	-0.233	1.0	1.01	Inf	0.972	1.01	0.0	0.972	0.01	-0.235	1.0	1.01
BT-20	AS605240	3	72	sigmoid	sigmoid	BT20 AS-605240 0 3 72	8	2.607	Inf	0.845	0.0823	4.13	0.662	0.292	0.729	0.0199	NA	Inf	0.81	0.897	3.97	0.589	0.284	0.712	0.0239	NA
Hs 578T	KIN001-244	3		sigmoid	sigmoid	Hs578T KIN001-244 3	8	2.888	Inf	0.866	0.00909	5.05	0.617	1.35	0.858	0.00289	NA	50.0	0.818	0.988	5.2	0.474	1.31	0.842	0.00391	NA
HCC38	AZD-6482	3	72	sigmoid	sigmoid	HCC38 AZD6482 0 3 72	8	1.420	Inf	0.821	0.0615	0.324	0.826	5.0	0.849	0.00342	NA	Inf	0.875	0.957	0.323	0.879	5.0	0.846	0.00367	NA
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
BT-549	AS605240	3	72	sigmoid	sigmoid	BT549 AS-605240 0 3 72	8	1.796	Inf	0.863	0.066	4.3	0.721	0.307	0.896	0.00112	NA	Inf	0.881	0.942	4.35	0.756	0.302	0.894	0.00118	NA
HCC38	AZD8055	3	72	sigmoid	sigmoid	HCC38 AZD8055 0 3 72	8	1.417	0.0464	0.0327	0.53	0.0463	0.000983	1.04	0.997	4.27e-08	NA	0.157	0.392	0.658	0.041	0.372	1.02	0.996	5.78e-08	NA
Hs 578T	MK2206	3		sigmoid	sigmoid	Hs578T MK-2206 3	8	2.883	Inf	0.737	0.0965	0.144	0.768	1.94	0.962	5.58e-05	NA	Inf	0.666	0.873	0.135	0.7	1.85	0.967	3.69e-05	NA
BT-20	AZD-6482	3	72	sigmoid	sigmoid	BT20 AZD6482 0 3 72	8	2.601	1.68	0.3	0.173	8.38	-1.0	0.685	0.959	6.72e-05	NA	1.5	0.326	0.805	1.5	0.0	0.733	0.925	0.000414	NA
HCC38	Dactolisib	3	72	sigmoid	sigmoid	HCC38 dactolisib 0 3 72	8	1.468	0.0082	-0.197	0.778	0.0127	-0.181	0.711	0.993	3.98e-07	NA	0.0268	0.262	0.497	0.00923	0.277	0.757	0.994	2.62e-07	NA

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)